Who Owns ImmuCell Stock?
NASDAQ: ICCCHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 20.30%
- Held by insiders
- 32.09%
- Institutional holders
- 35
- Institutions 20.3%
- Insiders 32.1%
- Public and other 47.6%
Who owns ImmuCell stock?
Institutional investors own about 20.3% of ImmuCell's shares, spread across 35 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 32.09% of ICCC.
The largest institutional holders are Vanguard Capital Management LLC (2.95%), Morgan Stanley (2.58%) and Renaissance Technologies, LLC (1.88%). Together, the top 10 institutions control 12.3% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their ICCC positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ICCC
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Vanguard Capital Management LLC | 268.13K | 2.95% | +3.0% |
| Morgan Stanley | 233.91K | 2.58% | +5.5% |
| Renaissance Technologies, LLC | 171.09K | 1.88% | +12.7% |
| Cresset Asset Management, LLC | 135.27K | 1.49% | 0.0% |
| Geode Capital Management, LLC | 72.27K | 0.80% | +9.9% |
| Dimensional Fund Advisors LP | 58.45K | 0.64% | +4.3% |
| Bleichroeder LP | 50.00K | 0.55% | -50.8% |
| Steadtrust LLC | 45.37K | 0.50% | -16.6% |
| Mesirow Financial Investment Management, Inc. | 42.48K | 0.47% | 0.0% |
| Citadel Advisors Llc | 40.50K | 0.45% | +13.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ICCC
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 181.08K | 1.99% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 78.99K | 0.87% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 33.51K | 0.37% |
| iShares Trust-iShares Micro-Cap ETF | 20.96K | 0.23% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Core Equity 2 Portfolio | 18.38K | 0.20% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 13.55K | 0.15% |
| Nationwide Mutual Funds-Nationwide Bailard Small Cap Value Fund | 10.10K | 0.11% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 9.45K | 0.10% |
| VANGUARD Inst. INDEX Fd.S-Vanguard Inst. Total Stock Market Index Fd. | 5.17K | 0.06% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Targeted Value Portfolio | 4.75K | 0.05% |
Frequently asked questions
Who is the largest shareholder of ImmuCell?
Vanguard Capital Management LLC is the largest institutional shareholder of ICCC, owning 2.95% of shares outstanding (268.13K shares) as of its latest 13F filing.
What percentage of ImmuCell is owned by institutions?
Institutions own about 20.3% of ICCC shares and 29.9% of the public float.
How much of ImmuCell do insiders own?
Insiders, such as officers and directors, own about 32.09% of ICCC shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.